Compound 1 Amine-Solvate Purification Without Column Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 1) generate impurities, requiring costly column chromatography for purification, and there is a need for a scalable, cost-effective process that meets regulatory purity requirements, as well as a stable polymorphic form of the drug.
Innovation Solution
A process involving the formation of amine solvates with certain organic amines to remove impurities and produce high-purity Compound 1, utilizing crystalline forms A and B polymorphs, which are thermodynamically stable and can be prepared without column chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column chromatography is used for purification, then purity requirement is met, but manufacturing cost and operational complexity increase significantly
Solution Approach 1:
The patent extracts and removes impurities through formation of amine solvates, where impurities are selectively removed from the reaction mixture by forming soluble amine solvates with the desired product, allowing filtration separation without requiring column chromatography equipment and operations
Solution Approach 2:
The patent introduces amine solvates as an intermediary mechanism to facilitate purification. The amine solvates act as a mediator that selectively complexes with the desired compound, enabling separation from impurities through filtration, thereby simplifying the purification process while maintaining high purity
2Manufacturing precision
If column chromatography is used for purification, then purity requirement is met, but manufacturing cost increases
Solution Approach 1:
The patent extracts and removes impurities through formation of amine solvates, where impurities are selectively removed from the reaction mixture by forming soluble amine solvates with the desired product, allowing filtration separation without requiring column chromatography equipment and operations
Solution Approach 2:
The patent employs readily available amine solvates as a cost-effective purification medium. These amine solvates are inexpensive, easily obtainable compounds that facilitate purification through simple filtration, replacing expensive column chromatography materials and reducing overall manufacturing costs
3Productivity
If conventional synthesis process is used, then Compound 1 is produced, but impurities are generated requiring additional purification steps
Solution Approach 1:
The patent converts the harmful impurities generated during synthesis into beneficial separation opportunities. By forming amine solvates with the desired product, the impurities are left behind in the reaction mixture, allowing their removal through filtration. This transforms the impurity problem into a simplified purification advantage, enhancing overall production efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high-purity Compound 1 production efficiently and cost-effectively, with stable polymorphic forms that maintain pharmaceutical properties and meet regulatory standards.
Implementation Method 1
Compound 1 can form amine solvates with certain organic amines. Formation of such amine solvates by Compound 1 enables removal of certain impurities generated in the synthesis of Compound 1
Implementation Method 2
The polymorphic behavior of small molecule drugs can be critical in pharmacology since the same small molecule can have different physical properties as a result of the arrangement of molecules in the crystal lattice
Data Source
AI summary
The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.